SCHEMBL22030293

SCHEMBL22030293

CCOC(=O)N[C@@H](C)C(=O)N(C)OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
FAAH O00519 1/20 0.36
ALDH1A1 P00352 5/20 0.35
HPGD P15428 2/20 0.35
MAPK1 P28482 1/20 0.34
GAA P10253 2/20 0.33
MGAM O43451 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
ATM Q13315 1/20 0.33
CHRNB2 P17787 3/20 0.33
CHRNA4 P43681 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10988574 1.00 CTSL (0.37) CTSLCTSBCTSSCTSKSMN1; SMN2
SCHEMBL12213979 0.84 SMN1; SMN2 (0.40) SMN1; SMN2ALDH1A1HPGDMAPK1CHRNB2
SCHEMBL10985225 0.84 CTSL (0.40) CTSLCTSBCTSSCTSKSMN1; SMN2
SCHEMBL12629160 0.83 FAAH (0.37) CTSLCTSBCTSSCTSKLMNA
SCHEMBL10980085 0.83 FAAH (0.37) CTSLCTSBCTSSCTSKLMNA
SCHEMBL21403713 0.81 ALDH1A1 (0.35) CTSLCTSBCTSSCTSKLMNA
SCHEMBL3154599 0.80 FAAH (0.37) CTSLCTSBCTSSCTSKMEN1
SCHEMBL288906 0.80 FAAH (0.37) CTSLCTSBCTSSCTSKMEN1
SCHEMBL15663456 0.80 FAAH (0.37) CTSLCTSBCTSSCTSKMEN1
SCHEMBL6625590 0.79 CYP2C9 (0.38) MEN1KMT2AFAAHTSHRACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200165211-A1 Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200165211-A1 Compounds, Compositions, and Methods for Treating T-Cell Acute Lymphoblastic Leukemia BCL9, BCL3, MCL1 CTSL 756/4885CTSB 1047/4885CTSS 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.